BIOC earnings

Biocept, Inc. (NASDAQ:BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. The conference call can be accessed at the time of the live call by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international callers.

Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update. "I'm exceptionally pleased with the progress being made with our FORESEE clinical trial, which is specifically designed to generate evidence of CNSide™'s clinical utility to support adoption into clinical care guidelines and further broaden physician use. Trial enrollment is running well in line with our plan, and we've now activated clinical sites in Dallas, Los Angeles and the San Francisco Bay Area," said Samuel D. Riccitelli, Biocept's Chairman, and interim President and CEO. "In our q

Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update. "I could not be prouder of my Biocept colleagues as together we have worked tirelessly to streamline operations, prioritize decisions to advance our corporate mission and carefully manage expenditures. We are more convinced than ever that our proprietary CNSide™ assay will improve the lives of patients with cancers that have metastasized to the central nervous system. To support this conviction, we have completed our evaluation of strategic alternatives and determined that the best course

CNSide™ study data featured in three poster presentations at leading neuro-oncology annual meeting Participates in UCSF investigator-initiated study to better understand the development and progression of metastatic breast cancer to the central nervous system CNSide orders increased 8% over 2Q 2022 and 176% versus 3Q 2021 Conference Call to be held November 28, 2022 at 4:00 p.m. Eastern time Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2022 and provides a business update. "Our third quarter financial results reflect solid increases in CNSide orders,

Included first revenue from biopharma collaborator using CNSide™ in their therapeutics clinical trial First site opened for patient enrollment in the FORESEE trial to generate evidence of CNSide's clinical utility Expanded the commercial availability of CNSide to metastatic melanoma CNSide™ orders increased 14% over 1Q 2022 and 212% versus 2Q 2021 Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2022 and provides a business update. "Today we are reporting strong progress in positioning Biocept as a leader in neurological tumor diagnostics," said Samuel D. Ric

Biocept, Inc. (NASDAQ:BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. The conference call can be accessed at the time of the live call by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international cal

Net revenues of $19.9 million up 12% over Q1 2021 CNSide™ assay volume up 219% over Q1 2021 and up 70% over Q4 2021 Expanded CNSide customer base with additional oncologists from six leading cancer centers Previews re-focused and rationalized strategy following comprehensive business review Business update conference call to be held June 7, 2022 at 4:00 p.m. ET Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2022 and provides a business update. "Net revenues for the first quarter increased 12% to $19.9 million, driven by RT-PCR COVID-19 testing services," said Sam

Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022. The delay is related to the ongoing accounting review of Biocept's financial statements as of and for the three months ended March 31, 2022, which ongoing review is a result of a change in circumstances at the U.S. Health Resources Services Administration (HRSA) and the resulting impact on its funding for reimbursement for COVID-19 testing services, including those performed by Biocept. Biocept expects to file its Form 10-Q on or before May 23, 2022. The company intends to issue

Fourth quarter net revenues of $14.0 million driven by RT-PCR COVID-19 testing volume Full year net revenues of $61.2 million increased 123% over the prior year Positive operating cash flow for 2021 of $3.7 million Cash and cash equivalents at 2021 year-end of $28.9 million CNSide™ sequential-quarter volume growth continued; academic customer base expanded Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2021 and provides a business update. "During the fourth quarter we expanded our CNSide customer base to include several additional prestigious academic

Biocept, Inc. (NASDAQ:BIOC) announces that it will release financial results for the three and 12 months ended December 31, 2021 and will file its Annual Report on Form 10-K with the Securities and Exchange Commission (SEC) on Thursday, March 31, 2022. Management will not hold an investment community conference call with the reporting of 2021 fourth quarter and full year financial results. Biocept plans to announce financial results for the three months ended March 30, 2022 in mid-May 2022. Management plans to hold an investment community conference call in conjunction with reporting first quarter 2022 financial results in which it plans to unveil the company's rationalized business strate

Revenues for the third quarter of $17.5 million, up 165% over prior-year quarter, driven by increased RT-PCR COVID-19 testing, resulting in profitability; cash balance of $27.7 million at quarter-end Robust CNSide™ sequential-quarter volume growth; continued customer base expansion Data generated by leading cancer center demonstrates superior performance of CNSide versus standard of care Conference call begins at 4:30 p.m. Eastern time today Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2021 and provides a business update. "With CNSide, our paradigm-c

Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15, 2021. The Company will host an investor conference call to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Date/Time: Monday, November 15, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here.   Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

Second quarter revenues of $12.0 million driven by RT-PCR COVID-19 testing Continued sequential-quarter CNSide™ volume growth with customer base expanding to more than 30 leading U.S. academic institutions, including multiple repeat users Issued coverage with high-value payment by Medicare for the Target Selector™ breast cancer assay to detect the HER2 biomarker Received nearly 500,000 samples for COVID-19 RT-PCR testing since June 2020 Conference call begins at 4:30 p.m. Eastern time today Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2021 and provides

Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and six months ended June 30, 2021 after the market closes on Monday, August 16, 2021. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Date/Time: Monday, August 16, 4:30 p.m. ET / 1:30 p.m. PT       Pre-Registration: Participants can pre-register for the conference call here.   Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to

Revenues of $17.8 million were driven by RT-PCR COVID-19 testing Initiated full commercial launch of CNSide™ cerebrospinal fluid assay for diagnosing and managing patients with metastatic cancer involving the central nervous system Received approximately 390,000 COVID-19 samples since June 2020 Hosted KOL webinar with leading neuro-oncologists discussing their use of CNSide and its importance in clinical decisions that affect patient outcomes Conference call begins at 4:30 p.m. Eastern time today Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2021 and provides

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2020 and provides a business update. “I’m exceptionally proud of the Biocept team for their enthusiasm and dedication in supporting the COVID-19 testing needs of our community while advancing our oncology business for a strong post-pandemic future,” said Michael Nall, President and CEO of Biocept. “Our COVID-19 testing has provided valuable information to our clients, which has helped contain viral spread. We received about 140,000 samples for COVID-19 testing during the fourth